CurrentCignaPolicy N/A

Topical Calcipotriene Products Drug Quantity Management Policy - Per Days

Sets drug quantity limits and exception criteria for topical calcipotriene products (single-entity and combination calcipotriene/betamethasone formulations) for Cigna-administered health plans. Affects prescribers, pharmacists, and utilization reviewers determining coverage and quantity overrides.

Policy Summary

PayerCigna

PolicyTopical Calcipotriene Products Drug Quantity Management Policy - Per Days

Policy CodePolicy N/A

Change TypeRoutine review — no material change

Effective DateN/A

Next Review DateNov 6, 2025

Key ActionIf requested quantity exceeds the drug quantity limit, submit a prior authorization request with documentation that the patient needs treatment for >8% body surface area to request an override; approvals are valid for 1 year.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

120 gRetail max (many single-entity) per 30 days

360 gHome delivery max (many single-entity) per 90 days

60 gRetail max (Enstilar/combination) per 30 days

≤100 g/weekCombination product weekly limit recommendation

1 year

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Quantity override criteria

Approve additional quantities when ALL of the following are met:

Base condition: Patient is using the product for plaque psoriasis (FDA-approved indication)

BSA requirement

Single-entity creams/foams/ointments: Dovonex 0.005% cream (generic), Sorilux foam (authorized generic), calcipotriene 0.005% ointment: approve up to 240 grams per 30 days (retail) and up to 720 grams per 90 days (home delivery)<=240 g/30d retail; <=720 g/90d HD
chunk 15
Solution (scalp): Calcipotriene 0.005% solution: approve up to 240 mL per 30 days (retail) and up to 720 mL per 90 days (home delivery)<=240 mL/30d retail; <=720 mL/90d HD
chunk 16
Combination products and Enstilar/Wynzora: Enstilar foam, Taclonex 0.005%/0.064% (ointment or suspension, generic), Wynzora: approve up to 120 grams per 30 days (retail) and up to 360 grams per 90 days (home delivery)<=120 g/30d retail; <=360 g/90d HD
chunk 16

No overrides are recommended for use in compounded formulations. Requests for additional quantity or prior authorization for compounded topical calcipotriene products should not be approved because overrides are explicitly not recommended for compounded preparations.

Any exception to the listed quantity limits other than the specified BSA-based criteria is considered not medically necessary. Only the predefined body-surface-area exceptions (see quantity override criteria) may justify approval of quantities above the standard limits.

Coding and Billing Guidance

General billing guidancemixed

No codes listed

BSA treatment threshold for overrides — > 8% BSA

BSA threshold for quantity overrideOverrides may be considered when the patient needs to treat greater than 8% of body surface area (BSA).

ApplicabilityApplies to topical calcipotriene single-entity and combination products when treating plaque psoriasis (FDA‑approved indication).

Documentation implicationRequested quantities above standard Drug Quantity Limits require documentation that >8% BSA needs treatment.

Provider Actions and Requirements

Documentation Required

Claim and documentation requirements

Claims for topical calcipotriene products must be reviewed against the member's specific benefit plan. Submiters should ensure claims use the most appropriate and current diagnosis and procedure/coding for the date of service. Claims submitted without covered code(s) or required documentation will be denied as not covered.

Verify member benefit coverage prior to submission
Include clinical documentation supporting medical necessity (e.g., indication of plaque psoriasis, estimated % body surface area treated)
When requesting quantities exceeding the Drug Quantity Limit (DQL), include documentation that the patient needs to treat >8% BSA and the specific quantity requested
Use appropriate NDC/CPT/HCPCS/ICD-10 codes consistent with the service and date of service

Prior Authorization

Quantity override / prior authorization

If the Drug Quantity Management rule is not met at point of service for the requested topical calcipotriene product, coverage will be determined by the Criteria in this policy. All approvals granted under this program are valid for 1 year.

Background

Topical vitamin D analogs (calcipotriene) and fixed calcipotriene/betamethasone combination products are indicated for the topical treatment of plaque psoriasis with product-specific age and site limitations. Single-agent calcipotriene formulations are typically applied twice daily, while combination products are usually applied once daily. Quantity management uses fingertip unit (FTU) and body surface area (BSA) estimates to determine expected product needs; one FTU is approximately 0.5 g and covers about 2% BSA (so 1 g covers ~4% BSA).

When treating more extensive disease, the policy allows quantity overrides only when the patient requires treatment of greater than 8% of body surface area, and product-specific maximums apply as listed (see quantity override criteria and quantity limits).

Definitions

Fingertip unit (FTU) definition

FTU definitionOne fingertip unit (FTU) is the amount squeezed from a standard tube along an adult fingertip (~0.5 g).

FTU coversOne FTU covers approximately 2% of an adult's total body surface area (BSA).

Gram to BSA conversionTherefore, 1 g of topical product is assumed to cover approximately 4% of BSA for one application.

Psoriasis severity by BSA — AAD‑NPF 2021

Mild psoriasisLess than 3% BSA affected.

Moderate psoriasis3% to 10% BSA affected.

Severe psoriasis

Initial Therapy Criteria

Product dosing and limits

Dosing/limits summary

Single-agent dosing: Calcipotriene single-agent products (cream, ointment, solution for scalp): apply twice daily (BID); product-specific availability and quantity limits are listed in the Drug Quantity Limits section.

chunks 5,11

Combination product dosing: Calcipotriene/betamethasone combination products (Enstilar, Taclonex, Wynzora): apply once daily (QD). Enstilar: apply QD for up to 4 weeks and do not exceed 60 g every 4 days per label. Taclonex and Wynzora: apply QD for up to 8 weeks and patients ≥18 years should not use more than 100 g per week.

chunks 11,12,14

Quantity limit overview: Standard retail quantity limits: many single-entity products 120 g (or mL) per 30 days and home delivery 360 g (or mL) per 90 days; Enstilar/Taclonex/Wynzora commonly 60 g per 30 days (180 g/90d HD). Exceptions for greater than 8% BSA allow higher limits as specified in the criteria.

Continuation Criteria

Approval duration

Approval duration: All approvals are provided for 1 year in duration.

chunk 7

Step Therapy / Operational Rules

Step	Requirement / action
1	Quantity management is enforced at point of service; if the Drug Quantity Management rule is not met for the requested medication at point of service, coverage will be determined by the criteria and may be denied. All approvals are provided for 1 year in duration.
2	If the requested quantity exceeds the Drug Quantity Limit, refer to the quantity override (prior authorization) criteria: additional quantities may be approved when the patient is using the product for plaque psoriasis and BSA-based exception criteria are met (e.g., treating >8% BSA with product‑specific maximums as listed).

Product-Specific Quantity Limits

Dovonex and single-entity calcipotriene products

Standard retail limitDovonex (calcipotriene 0.005% cream) retail maximum: 120 g per 30 days.

Standard home delivery limitDovonex home delivery maximum: 360 g per 90 days.

BSA‑based exception limitIf treating >8% BSA, approve up to 240 g per 30 days (retail) and up to 720 g per 90 days (home delivery).

Sorilux (authorized generic)

Standard retail limitSorilux (calcipotriene 0.005% foam, authorized generic) retail maximum: 120 g per 30 days.

Standard home delivery limitSorilux home delivery maximum: 360 g per 90 days.

Policy Summary

PayerCigna

PolicyTopical Calcipotriene Products Drug Quantity Management Policy - Per Days

Policy CodePolicy N/A

Change TypeRoutine review — no material change

Effective DateN/A

Next Review DateNov 6, 2025

SourceLink

On This Page

Coverage may be denied at point of sale if quantity rule not met
Providers should submit a prior authorization request with supporting documentation when requesting quantities above the DQL

Denial Risk

Quantity management denial trigger

If a requested quantity exceeds the configured Drug Quantity Limit and the approval criteria are not met or not documented, the claim is at risk for denial. Ensure the request meets the policy criteria for the specific formulation and quantity thresholds.

Denial risk when documentation does not show >8% body surface area involvement for the requested product and quantity
For retail fills exceeding DQL, ensure documentation supports quantities up to the policy limits (see Criteria for product-specific limits)

Note

Provider action highlight

Providers should initiate prior authorization or quantity override requests when billing amounts exceed Drug Quantity Limits. Highlighted actions: verify benefits, attach clinical notes showing indication and % BSA, and specify the dispensing frequency (retail vs home delivery).

For override requests, include: diagnosis of plaque psoriasis, documentation of >8% BSA treated, and exact quantity requested (grams or mL and whether retail or home delivery)
Retain supporting medical records in case of audit or peer review

Greater than 10% BSA affected.

BSA‑based exception limit

If treating >8% BSA, exception may allow up to 240 g per 30 days (retail) and 720 g per 90 days (home delivery).

Calcipotriene 0.005% solution (scalp)

Standard retail limitCalcipotriene 0.005% solution (scalp) retail maximum: 120 mL per 30 days.

Standard home delivery limitCalcipotriene solution home delivery maximum: 360 mL per 90 days.

BSA‑based exception limitIf treating >8% BSA, exception may allow up to 240 mL per 30 days (retail) and 720 mL per 90 days (home delivery).

Enstilar, Taclonex, Wynzora (combination products)

Common retail limitEnstilar, Taclonex, Wynzora retail maximum commonly: 60 g per 30 days for some presentations.

Common home delivery limitHome delivery maximum commonly: 180 g per 90 days for these combination products.

Label weekly use guidanceCombination products (Enstilar/Taclonex/Wynzora): adults should not exceed 100 g per week (do not use >100 g/week per label).

BSA‑based exception limitIf treating >8% BSA, approve up to 120 g per 30 days (retail) and 360 g per 90 days (home delivery).